SomaLogic, Inc. (SLGC)

NASDAQ: SLGC · IEX Real-Time Price · USD
+0.02 (0.74%)
At close: Nov 27, 2023, 4:00 PM
-0.02 (-0.73%)
After-hours: Nov 27, 2023, 5:07 PM EST

Company Description

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.

It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.

The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development.

Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others.

The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions.

The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits.

The company was founded in 1999 and is headquartered in Boulder, Colorado.

SomaLogic, Inc.
SomaLogic logo
Country United States
Founded 2000
Industry Health Information Services
Sector Healthcare
Employees 451
CEO Adam Taich

Contact Details

C/o Somalogic, Inc., 2945 Wilderness Place
Boulder, Colorado 80301
United States
Phone (303) 625-9000

Stock Details

Ticker Symbol SLGC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001837412
CUSIP Number 83444K105
ISIN Number US83444K1051
Employer ID 85-4298912
SIC Code 8731

Key Executives

Name Position
Troy M. Cox M.B.A. Executive Chairman
Dr. Roy Smythe M.D. Chief Executive Officer and Director
Shaun M. Blakeman Chief Financial Officer
Dr. Jason Cleveland Ph.D. Chief Technology Officer
Dr. Nebojsa Janjic Ph.D. Chief Science Officer
Ruben Gutierrez J.D. General Counsel
Alison Marie Roelke Senior Vice President of People and Culture
Dr. Stephen A. Williams BS, MB, Ph.D. Chief Medical Officer
Todd Johnson Executive Vice President of Diagnostics Business Unit
Adam Taich Executive Vice President of Life Sciences Business Unit

Latest SEC Filings

Date Type Title
Nov 21, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 21, 2023 8-K Current Report
Nov 8, 2023 10-Q Quarterly Report
Nov 8, 2023 8-K Current Report
Nov 8, 2023 425 Filing
Oct 4, 2023 425 Filing
Oct 4, 2023 425 Filing
Oct 4, 2023 425 Filing
Oct 4, 2023 425 Filing
Oct 4, 2023 425 Filing